A Prospective, Multi-center, Observational Study to Assess the Tolerability of Interferon-beta 1-A (Rebif) Therapy for Korean Patients With Multiple Sclerosis.
Phase of Trial: Phase IV
Latest Information Update: 16 Apr 2014
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Merck KGaA
- 09 Aug 2012 Actual end date Nov 2011 added as reported by ClinicalTrials.gov.
- 01 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.